Genprex (NASDAQ:GNPX) Short Interest Update

Genprex (NASDAQ:GNPX) was the recipient of a significant decrease in short interest in July. As of July 31st, there was short interest totaling 36,884 shares, a decrease of 95.8% from the July 15th total of 884,893 shares. Approximately 7.3% of the company’s stock are sold short. Based on an average daily volume of 50,133 shares, the days-to-cover ratio is presently 0.7 days.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Genprex in a report on Friday, July 17th. Wall Street Zen upgraded shares of Genprex from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Genprex presently has a consensus rating of “Sell”.

Genprex Price Performance

Shares of GNPX stock traded up $0.28 during trading hours on Tuesday, hitting $4.47. The stock had a trading volume of 156,429 shares, compared to its average volume of 218,010. The firm has a market capitalization of $2.23 million, a PE ratio of -0.01 and a beta of -0.88. Genprex has a twelve month low of $4.00 and a twelve month high of $1,210.00. The stock’s 50 day moving average is $10.11 and its 200 day moving average is $26.23.

Genprex (NASDAQ:GNPX) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($14.08) EPS for the quarter.

Institutional Investors Weigh In On Genprex

Several hedge funds have recently made changes to their positions in the business. Manchester Financial Inc. purchased a new position in shares of Genprex during the first quarter worth about $36,000. Mayflower Financial Advisors LLC purchased a new stake in Genprex during the 1st quarter valued at approximately $36,000. Finally, Susquehanna International Group LLP lifted its position in Genprex by 11.7% during the 3rd quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock worth $58,000 after acquiring an additional 35,661 shares during the period. Institutional investors and hedge funds own 14.05% of the company’s stock.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.